메뉴 건너뛰기




Volumn 118, Issue 2, 2012, Pages 300-311

Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Dasatinib; Imatinib; Nilotinib

Indexed keywords

ARGININE; BCR ABL PROTEIN; CYTARABINE; DASATINIB; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; IMATINIB; INTERFERON; ISOLEUCINE; LEUCINE; METHIONINE; NILOTINIB; PEGINTERFERON ALPHA; PHENYLALANINE; PROLINE; THREONINE; TYROSINE; VALINE;

EID: 83755171527     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26280     Document Type: Review
Times cited : (13)

References (89)
  • 1
    • 0000286732 scopus 로고
    • A minute chromosome in human chronic granulocytic leukemia
    • Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132: 1497.
    • (1960) Science , vol.132 , pp. 1497
    • Nowell, P.C.1    Hungerford, D.A.2
  • 2
    • 0015694748 scopus 로고
    • A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
    • Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-293.
    • (1973) Nature , vol.243 , pp. 290-293
    • Rowley, J.D.1
  • 3
    • 0020972981 scopus 로고
    • Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia
    • Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280. (Pubitemid 14232360)
    • (1983) Nature , vol.306 , Issue.5940 , pp. 277-280
    • Bartram, C.R.1    De Klein, A.2    Hagemeijer, A.3
  • 4
    • 0021346853 scopus 로고
    • Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
    • Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-99. (Pubitemid 14155374)
    • (1984) Cell , vol.36 , Issue.1 , pp. 93-99
    • Groffen, J.1    Stephenson, J.R.2    Heisterkamp, N.3
  • 5
    • 0025348013 scopus 로고
    • Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
    • Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082.
    • (1990) Science , vol.247 , pp. 1079-1082
    • Lugo, T.G.1    Pendergast, A.M.2    Muller, A.J.3
  • 7
    • 33947224197 scopus 로고    scopus 로고
    • New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
    • Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006; 145:913-923. (Pubitemid 351639967)
    • (2006) Annals of Internal Medicine , vol.145 , Issue.12 , pp. 913-923
    • Kantarjian, H.M.1    Talpaz, M.2    Giles, F.3    O'Brien, S.4    Cortes, J.5
  • 8
    • 84855482586 scopus 로고    scopus 로고
    • National Institutes of Health. Surveillance Epidemiology and End Results web site. Accessed September 3, 2010
    • National Cancer Institute, National Institutes of Health. Surveillance Epidemiology and End Results web site. Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia. http://seer.cancer.gov/statfacts/html/ cmyl.html. Accessed September 3, 2010.
    • Finding Cancer Statistics: Cancer Stat Fact Sheets: Chronic Myeloid Leukemia
  • 9
    • 33644525274 scopus 로고    scopus 로고
    • Gene expression changes associated with progression and response in chronic myeloid leukemia
    • Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103:2794-2799.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 2794-2799
    • Radich, J.P.1    Dai, H.2    Mao, M.3
  • 10
    • 0033614446 scopus 로고    scopus 로고
    • Chronic myeloid leukemia
    • DOI 10.1056/NEJM199904293401706
    • Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340. (Pubitemid 29196596)
    • (1999) New England Journal of Medicine , vol.340 , Issue.17 , pp. 1330-1340
    • Sawyers, C.L.1
  • 12
    • 73349122639 scopus 로고    scopus 로고
    • Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
    • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J ClinOncol. 2009;27:6041-6051.
    • (2009) J ClinOncol , vol.27 , pp. 6041-6051
    • Baccarani, M.1    Cortes, J.2    Pane, F.3
  • 15
    • 77949767505 scopus 로고    scopus 로고
    • International randomized study of interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 1126
    • Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1126.
    • (2009) Blood , vol.114
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3
  • 16
    • 71849108124 scopus 로고    scopus 로고
    • Imatinib resistance and/or intolerance in clinical practice in Europe. The "Unmet Needs in CML and Ph+ ALL" (UNIC) study
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 1951
    • Michallet M, Morra E, Steegman J, et al. Imatinib resistance and/or intolerance in clinical practice in Europe. The "Unmet Needs in CML and Ph+ ALL" (UNIC) study [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110, Abstract 1951.
    • (2007) Blood , vol.110
    • Michallet, M.1    Morra, E.2    Steegman, J.3
  • 17
    • 84855494380 scopus 로고    scopus 로고
    • Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice
    • [abstract]. Abstract 6595
    • Davis C, Sanders L, Hirji I, et al. Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 6595.
    • (2008) J Clin Oncol , vol.26 , Issue.MAY 20 SUPPL.
    • Davis, C.1    Sanders, L.2    Hirji, I.3
  • 18
    • 49149111543 scopus 로고    scopus 로고
    • Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
    • de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3363.
    • (2008) J Clin Oncol , vol.26 , pp. 3358-3363
    • De Lavallade, H.1    Apperley, J.F.2    Khorashad, J.S.3
  • 19
    • 54049130762 scopus 로고    scopus 로고
    • A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
    • Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963-1966.
    • (2008) Leukemia , vol.22 , pp. 1963-1966
    • Lucas, C.M.1    Wang, L.2    Austin, G.M.3
  • 21
    • 33748133844 scopus 로고    scopus 로고
    • Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials
    • DOI 10.1182/blood-2006-02-001495
    • Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between 2 phase 3 trials. Blood. 2006;108:1478-1484. (Pubitemid 44316111)
    • (2006) Blood , vol.108 , Issue.5 , pp. 1478-1484
    • Roy, L.1    Guilhot, J.2    Krahnke, T.3    Guerci-Bresler, A.4    Druker, B.J.5    Larson, R.A.6    O'Brien, S.7    So, C.8    Massimini, G.9    Guilhot, F.10
  • 22
    • 67349233062 scopus 로고    scopus 로고
    • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    • Hochhaus A, O'Brien S, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-1061.
    • (2009) Leukemia , vol.23 , pp. 1054-1061
    • Hochhaus, A.1    O'Brien, S.2    Guilhot, F.3
  • 23
    • 58149396984 scopus 로고    scopus 로고
    • European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    • Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437-4444.
    • (2008) Blood , vol.112 , pp. 4437-4444
    • Marin, D.1    Milojkovic, D.2    Olavarria, E.3
  • 26
    • 35948937212 scopus 로고    scopus 로고
    • A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response
    • DOI 10.1158/1078-0432.CCR-07-1112
    • Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13:6136-6143. (Pubitemid 350075073)
    • (2007) Clinical Cancer Research , vol.13 , Issue.20 , pp. 6136-6143
    • Press, R.D.1    Galderisi, C.2    Yang, R.3    Rempfer, C.4    Willis, S.G.5    Mauro, M.J.6    Druker, B.J.7    Deininger, M.W.N.8
  • 27
    • 57049180944 scopus 로고    scopus 로고
    • Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: A 6-year follow-up
    • Qin YZ, Jiang B, Jiang Q, et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol. 2009;88:37-41.
    • (2009) Ann Hematol , vol.88 , pp. 37-41
    • Qin, Y.Z.1    Jiang, B.2    Jiang, Q.3
  • 29
    • 77958595179 scopus 로고    scopus 로고
    • Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    • Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758-3765.
    • (2010) Blood , vol.116 , pp. 3758-3765
    • Hughes, T.P.1    Hochhaus, A.2    Branford, S.3
  • 30
    • 77953691179 scopus 로고    scopus 로고
    • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    • Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-2259.
    • (2010) N Engl J Med , vol.362 , pp. 2251-2259
    • Saglio, G.1    Kim, D.-W.2    Issaragrisil, S.3
  • 31
    • 77953725855 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270.
    • (2010) N Engl J Med , vol.362 , pp. 2260-2270
    • Kantarjian, H.1    Shah, N.P.2    Hochhaus, A.3
  • 32
    • 79952787880 scopus 로고    scopus 로고
    • A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): The S0325 Intergroup Trial
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract LBA-6
    • Radich JP, Kopecky KJ, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract LBA-6.
    • (2010) Blood , vol.116
    • Radich, J.P.1    Kopecky, K.J.2    Kamel-Reid, S.3
  • 33
    • 77957026184 scopus 로고    scopus 로고
    • Practical considerations for monitoring patients with chronic myeloid leukemia
    • Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukemia. Semin Hematol. 2010;47:327-334.
    • (2010) Semin Hematol , vol.47 , pp. 327-334
    • Branford, S.1    Hughes, T.P.2
  • 34
    • 37249016890 scopus 로고    scopus 로고
    • BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
    • DOI 10.1158/1078-0432.CCR-07-0844
    • Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13:7080-7085. (Pubitemid 350276891)
    • (2007) Clinical Cancer Research , vol.13 , Issue.23 , pp. 7080-7085
    • Branford, S.1    Seymour, J.F.2    Grigg, A.3    Arthur, C.4    Rudzki, Z.5    Lynch, K.6    Hughes, T.7
  • 35
    • 78049528573 scopus 로고    scopus 로고
    • Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial
    • Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035.
    • (2010) Lancet Oncol , vol.11 , pp. 1029-1035
    • Mahon, F.X.1    Rea, D.2    Guilhot, F.3
  • 36
    • 33750615550 scopus 로고    scopus 로고
    • Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
    • Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood. 2006;108:2811-2813.
    • (2006) Blood , vol.108 , pp. 2811-2813
    • Kovitz, C.1    Kantarjian, H.2    Garcia-Manero, G.3    Abruzzo, L.V.4    Cortes, J.5
  • 38
    • 35548971639 scopus 로고    scopus 로고
    • Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
    • DOI 10.1182/blood-2007-01-070045
    • Jabbour E, Kantarjian HM, Abruzzo LV, et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007;110:2991-2995. (Pubitemid 350006953)
    • (2007) Blood , vol.110 , Issue.8 , pp. 2991-2995
    • Jabbour, E.1    Kantarjian, H.M.2    Abruzzo, L.V.3    O'Brien, S.4    Garcia-Manero, G.5    Verstovsek, S.6    Shan, J.7    Rios, M.B.8    Cortes, J.9
  • 39
    • 65649147887 scopus 로고    scopus 로고
    • Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    • [abstract]. Abstract 7017
    • Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol. 2008;26(May 20 suppl). Abstract 7017.
    • (2008) J Clin Oncol , vol.26 , Issue.MAY 20 SUPPL.
    • Giles, F.J.1    Larson, R.A.2    Kantarjian, H.M.3
  • 40
    • 76549116248 scopus 로고    scopus 로고
    • Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
    • Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95:232-240.
    • (2010) Haematologica , vol.95 , pp. 232-240
    • Shah, N.P.1    Kim, D.W.2    Kantarjian, H.3
  • 41
    • 57349124075 scopus 로고    scopus 로고
    • Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: Outcome of the patients alive after a 6-year follow-up
    • Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792-1796.
    • (2008) Haematologica , vol.93 , pp. 1792-1796
    • Palandri, F.1    Castagnetti, F.2    Testoni, N.3
  • 42
    • 59549084574 scopus 로고    scopus 로고
    • The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up
    • Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94:205-212.
    • (2009) Haematologica , vol.94 , pp. 205-212
    • Palandri, F.1    Castagnetti, F.2    Alimena, G.3
  • 43
    • 60049086655 scopus 로고    scopus 로고
    • Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START Program
    • [abstract]. Abstract 0880
    • Saglio G, Dombret H, Rea D, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START Program [abstract]. Haematologica. 2008;93(S1)349. Abstract 0880.
    • (2008) Haematologica , vol.93 , Issue.S1 , pp. 349
    • Saglio, G.1    Dombret, H.2    Rea, D.3
  • 44
    • 67650607999 scopus 로고    scopus 로고
    • Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median followup
    • Kantarjian H, Cortes J, Kim D-W, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median followup. Blood. 2009;113:6322-6329.
    • (2009) Blood , vol.113 , pp. 6322-6329
    • Kantarjian, H.1    Cortes, J.2    Kim, D.-W.3
  • 45
    • 72149111552 scopus 로고    scopus 로고
    • Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    • [abstract]. Abstract 7057
    • Le Coutre PD, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol. 2009;27(15S). Abstract 7057.
    • (2009) J Clin Oncol , vol.27 , Issue.15 S
    • Le Coutre, P.D.1    Giles, F.2    Hochhaus, A.3
  • 46
    • 75749090051 scopus 로고    scopus 로고
    • Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
    • Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28:392-397.
    • (2010) J Clin Oncol , vol.28 , pp. 392-397
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3
  • 47
    • 75749129911 scopus 로고    scopus 로고
    • Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
    • Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28:398-404.
    • (2010) J Clin Oncol , vol.28 , pp. 398-404
    • Cortes, J.E.1    Jones, D.2    O'Brien, S.3
  • 48
    • 77954799488 scopus 로고    scopus 로고
    • Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: Clinical response, safety, and long-term outcomes
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 1129
    • Kantarjian HM, Giles FJ, Bhalla KN, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;113. Abstract 1129.
    • (2009) Blood , vol.113
    • Kantarjian, H.M.1    Giles, F.J.2    Bhalla, K.N.3
  • 50
    • 10744232328 scopus 로고    scopus 로고
    • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
    • DOI 10.1182/blood-2002-09-2896
    • Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283. (Pubitemid 36759665)
    • (2003) Blood , vol.102 , Issue.1 , pp. 276-283
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3    Parkinson, I.4    Grigg, A.5    Szer, J.6    Taylor, K.7    Herrmann, R.8    Seymour, J.F.9    Arthur, C.10    Joske, D.11    Lynch, K.12    Hughes, T.13
  • 52
    • 15944404601 scopus 로고    scopus 로고
    • The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    • DOI 10.1182/blood-2004-08-3097
    • Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653. (Pubitemid 40446252)
    • (2005) Blood , vol.105 , Issue.7 , pp. 2640-2653
    • Deininger, M.1    Buchdunger, E.2    Druker, B.J.3
  • 53
    • 61849163272 scopus 로고    scopus 로고
    • Molecular biology of bcr-abl1-positive chronic myeloid leukemia
    • Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113: 1619-1630.
    • (2009) Blood , vol.113 , pp. 1619-1630
    • Quintas-Cardama, A.1    Cortes, J.2
  • 56
    • 54349089682 scopus 로고    scopus 로고
    • Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of progression
    • Khorashad JS, de Lavallade H, Apperley J, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of progression. J Clin Oncol. 2008;26:4806-4813.
    • (2008) J Clin Oncol , vol.26 , pp. 4806-4813
    • Khorashad, J.S.1    De Lavallade, H.2    Apperley, J.3
  • 57
    • 35448967331 scopus 로고    scopus 로고
    • Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
    • DOI 10.1016/S1470-2045(07)70342-X, PII S147020450770342X
    • Apperley JF. Part 1: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8: 1018-1029. (Pubitemid 47629897)
    • (2007) Lancet Oncology , vol.8 , Issue.11 , pp. 1018-1029
    • Apperley, J.F.1
  • 58
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • DOI 10.1126/science.1062538
    • Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880. (Pubitemid 32743979)
    • (2001) Science , vol.293 , Issue.5531 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Nagesh, R.P.6    Sawyers, C.L.7
  • 60
    • 9444282642 scopus 로고    scopus 로고
    • Active transport of imatinib into and out of cells: Implications for drug resistance
    • DOI 10.1182/blood-2003-12-4276
    • Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739-3745. (Pubitemid 39564452)
    • (2004) Blood , vol.104 , Issue.12 , pp. 3739-3745
    • Thomas, J.1    Wang, L.2    Clark, R.E.3    Pirmohamed, M.4
  • 61
    • 26944452899 scopus 로고    scopus 로고
    • Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia
    • DOI 10.1038/sj.leu.2403853, PII 2403853
    • Zong Y, Zhou S, Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia. 2005;19:1590-1596. (Pubitemid 43090403)
    • (2005) Leukemia , vol.19 , Issue.9 , pp. 1590-1596
    • Zong, Y.1    Zhou, S.2    Sorrentino, B.P.3
  • 62
    • 37049028176 scopus 로고    scopus 로고
    • Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity
    • DOI 10.1182/blood-2007-06-093617
    • White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007; 110:4064-4072. (Pubitemid 350248463)
    • (2007) Blood , vol.110 , Issue.12 , pp. 4064-4072
    • White, D.L.1    Saunders, V.A.2    Dang, P.3    Engler, J.4    Venables, A.5    Zrim, S.6    Zannettino, A.7    Lynch, K.8    Manley, P.W.9    Hughes, T.10
  • 63
    • 79956130861 scopus 로고    scopus 로고
    • Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
    • [abstract]. Abstract 6512
    • Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily [abstract]. J Clin Oncol. 2010;28(15S). Abstract 6512.
    • (2010) J Clin Oncol , vol.28 , Issue.15 S
    • Shah, N.P.1    Cortes, J.E.2    Schiffer, C.A.3
  • 64
    • 79952014676 scopus 로고    scopus 로고
    • Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP)
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 1122
    • Shah N, Bahceci E, Lambert A, et al. Resistance, outcome and the development of mutations with dasatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1122.
    • (2009) Blood , vol.114
    • Shah, N.1    Bahceci, E.2    Lambert, A.3
  • 65
    • 70349306853 scopus 로고    scopus 로고
    • Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: Response dynamics and predictive value
    • Hochhaus A, Muller MC, Radich J, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia. 2009;23:1628-1633.
    • (2009) Leukemia , vol.23 , pp. 1628-1633
    • Hochhaus, A.1    Muller, M.C.2    Radich, J.3
  • 66
    • 76249090055 scopus 로고    scopus 로고
    • Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?
    • Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009; 114:5426-5435.
    • (2009) Blood , vol.114 , pp. 5426-5435
    • Branford, S.1    Melo, J.V.2    Hughes, T.P.3
  • 67
    • 70349245253 scopus 로고    scopus 로고
    • Long-term outcome with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
    • Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009;114:2037-2043.
    • (2009) Blood , vol.114 , pp. 2037-2043
    • Jabbour, E.1    Jones, D.2    Kantarjian, H.M.3
  • 69
    • 79551516839 scopus 로고    scopus 로고
    • Response and outcomes to nilotinib at 24 months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 1130
    • Radich JP, Martinelli G, Hochhaus A, et al. Response and outcomes to nilotinib at 24 months in imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) and accelerated phase (CML-AP) with and without BCR-ABL mutations [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 1130.
    • (2009) Blood , vol.114
    • Radich, J.P.1    Martinelli, G.2    Hochhaus, A.3
  • 70
    • 70249105789 scopus 로고    scopus 로고
    • Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase
    • Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204-4210.
    • (2009) J Clin Oncol , vol.27 , pp. 4204-4210
    • Hughes, T.1    Saglio, G.2    Branford, S.3
  • 71
    • 73949105873 scopus 로고    scopus 로고
    • Dasatinib treatment of chronic phase chronic myeloid leukemia: Analysis of responses according to pre-existing BCR-ABL mutations
    • Muller MC, Cortes JC, Kim D-W, et al. Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood. 2009;114:4944-4953.
    • (2009) Blood , vol.114 , pp. 4944-4953
    • Muller, M.C.1    Cortes, J.C.2    Kim, D.-W.3
  • 72
    • 50949119729 scopus 로고    scopus 로고
    • Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    • Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008;112:516-518.
    • (2008) Blood , vol.112 , pp. 516-518
    • Tam, C.S.1    Kantarjian, H.2    Garcia-Manero, G.3
  • 73
    • 76549114789 scopus 로고    scopus 로고
    • Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    • Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010; 95:224-231.
    • (2010) Haematologica , vol.95 , pp. 224-231
    • Milojkovic, D.1    Nicholson, E.2    Apperley, J.F.3
  • 74
    • 77953208869 scopus 로고    scopus 로고
    • + CML chronic phase patients: First results from the randomized CELSG phase III CML 11 "ISTA-HIT" study
    • + CML chronic phase patients: first results from the randomized CELSG phase III CML 11 "ISTA-HIT" study. Haematologica. 2010;95:908-913.
    • (2010) Haematologica , vol.95 , pp. 908-913
    • Petzer, A.L.1    Wolf, D.2    Fong, D.3
  • 75
    • 75749105885 scopus 로고    scopus 로고
    • Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study
    • Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28:424-430.
    • (2010) J Clin Oncol , vol.28 , pp. 424-430
    • Cortes, J.E.1    Baccarani, M.2    Guilhot, F.3
  • 77
    • 43249083718 scopus 로고    scopus 로고
    • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study
    • Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
    • (2008) Blood , vol.111 , pp. 4022-4028
    • Larson, R.A.1    Druker, B.J.2    Guilhot, F.3
  • 78
    • 57049115901 scopus 로고    scopus 로고
    • Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
    • Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009;33:271-275.
    • (2009) Leuk Res , vol.33 , pp. 271-275
    • Forrest, D.L.1    Trainor, S.2    Brinkman, R.R.3
  • 79
    • 78650625238 scopus 로고    scopus 로고
    • Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
    • SPIRIT Investigators; France Intergroupe des Leucemies Myelloides Chroniques (Fi-LMC)
    • Preudhomme C, Guilhot J, Nicolini FE, et al. SPIRIT Investigators; France Intergroupe des Leucemies Myelloides Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363:2511-2521.
    • (2010) N Engl J Med , vol.363 , pp. 2511-2521
    • Preudhomme, C.1    Guilhot, J.2    Nicolini, F.E.3
  • 80
    • 84855507276 scopus 로고    scopus 로고
    • Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg plus IFN in CML: The randomized German CML-Study IV
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 357
    • Hehlmann R, Jung-Munkwitz S, Lauseker M, et al. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg plus IFN in CML: the randomized German CML-Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 357.
    • (2010) Blood , vol.116
    • Hehlmann, R.1    Jung-Munkwitz, S.2    Lauseker, M.3
  • 81
    • 79251527895 scopus 로고    scopus 로고
    • Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte- macrophage colony-stimulating factor
    • Cortes J, Quintas-Cardama A, Jones D, et al. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011;117:572-580.
    • (2011) Cancer , vol.117 , pp. 572-580
    • Cortes, J.1    Quintas-Cardama, A.2    Jones, D.3
  • 83
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study
    • Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401-5411.
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    Van Lierde, M.A.2    De Bock, R.3
  • 84
    • 77952467377 scopus 로고    scopus 로고
    • Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    • Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381-2388.
    • (2010) J Clin Oncol , vol.28 , pp. 2381-2388
    • Marin, D.1    Bazeos, A.2    Mahon, F.X.3
  • 85
    • 77950402447 scopus 로고    scopus 로고
    • Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 338
    • Cortes J, Borthakur G, O'Brien S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 338.
    • (2009) Blood , vol.114
    • Cortes, J.1    Borthakur, G.2    O'Brien, S.3
  • 86
    • 77950426669 scopus 로고    scopus 로고
    • Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 341
    • Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114 Abstract 341.
    • (2009) Blood , vol.114
    • Cortes, J.1    O'Brien, S.2    Jones, D.3
  • 87
    • 79953320397 scopus 로고    scopus 로고
    • Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): Results of a phase 2 GIMEMA CML Working Party clinical trial
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 359
    • Rosti G, Castagnetti F, Gugliotta G, et al. Excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a phase 2 GIMEMA CML Working Party clinical trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 359.
    • (2010) Blood , vol.116
    • Rosti, G.1    Castagnetti, F.2    Gugliotta, G.3
  • 88
    • 79952038063 scopus 로고    scopus 로고
    • ENESTnd update: Continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 207
    • Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 207.
    • (2010) Blood , vol.116
    • Hughes, T.P.1    Hochhaus, A.2    Saglio, G.3
  • 89
    • 79952038795 scopus 로고    scopus 로고
    • Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up
    • [abstract]. (ASH Annual Meeting Abstracts). Abstract 206
    • Shah N, Kantarjian H, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116. Abstract 206.
    • (2010) Blood , vol.116
    • Shah, N.1    Kantarjian, H.2    Hochhaus, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.